NP 61

Drug Profile

NP 61

Alternative Names: NP 0361; NP-61

Latest Information Update: 07 Mar 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuropharma
  • Class Antidementias; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 18 Dec 2012 Noscira is in liquidation
  • 18 Dec 2012 Discontinued - Phase-I for Alzheimer's disease in Ireland (PO)
  • 10 Mar 2009 Noscira is seeking partnership opportunities for further development and commercialisation of NP 61 worldwide, except the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top